Key Laboratory of Glycoconjugate Research, Ministry of Public Health, Shanghai Medical College of Fudan University, Shanghai, People’s Republic of China.
J Clin Invest. 2012 Jul;122(7):2554-66. doi: 10.1172/JCI58488. Epub 2012 Jun 1.
Coordinated translation initiation is coupled with cell cycle progression and cell growth, whereas excessive ribosome biogenesis and translation initiation often lead to tumor transformation and survival. Hepatocellular carcinoma (HCC) is among the most common and aggressive cancers worldwide and generally displays inherently high resistance to chemotherapeutic drugs. We found that RACK1, the receptor for activated C-kinase 1, was highly expressed in normal liver and frequently upregulated in HCC. Aberrant expression of RACK1 contributed to in vitro chemoresistance as well as in vivo tumor growth of HCC. These effects depended on ribosome localization of RACK1. Ribosomal RACK1 coupled with PKCβII to promote the phosphorylation of eukaryotic initiation factor 4E (eIF4E), which led to preferential translation of the potent factors involved in growth and survival. Inhibition of PKCβII or depletion of eIF4E abolished RACK1-mediated chemotherapy resistance of HCC in vitro. Our results imply that RACK1 may function as an internal factor involved in the growth and survival of HCC and suggest that targeting RACK1 may be an efficacious strategy for HCC treatment.
协调的翻译起始与细胞周期进程和细胞生长相关联,而核糖体生物发生和翻译起始的过度往往导致肿瘤转化和存活。肝细胞癌(HCC)是全球最常见和侵袭性的癌症之一,通常对化疗药物具有固有抗性。我们发现,激活 C 激酶 1 的受体 RACK1 在正常肝脏中高度表达,并且在 HCC 中经常上调。RACK1 的异常表达有助于 HCC 的体外化疗耐药以及体内肿瘤生长。这些影响取决于 RACK1 的核糖体定位。核糖体 RACK1 与 PKCβII 结合,促进真核起始因子 4E(eIF4E)的磷酸化,从而导致与生长和存活相关的强效因子优先翻译。抑制 PKCβII 或耗尽 eIF4E 可消除 RACK1 介导的 HCC 体外化疗耐药性。我们的结果表明,RACK1 可能作为 HCC 生长和存活的内在因素发挥作用,并表明靶向 RACK1 可能是 HCC 治疗的有效策略。